52 completed. 52 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 52 | Completed 52 |
| Phase 1 | 7 | Completed 7 |
| Phase 3 | 2 | Completed 2 |
Follow Chronic Hepatitis b: new trials by email Literature Review of Chronic Hepatitis b trials Research Report on Chronic Hepatitis b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RBD1016 in CHB Participants RBD1016 - Chronic Hepatitis b | Phase 2 | Completed | Suzhou Ribo Life Science Co. Ltd. | 48 | 2023-10-11 | 2025-12-09 |
| A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) HRS9950 tablets, HRS9950 placebo tablets - Chronic Hepatitis B | Phase 2 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 54 | 2023-07-28 | 2024-12-03 |
| Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets GST-HG141 - Chronic Hepatitis b | Phase 2 | Completed | Fujian Akeylink Biotechnology Co., Ltd. | 90 | 2023-01-03 | 2025-03-05 |
| Efficacy of VTP-300 in Chronic Hepatitis B Infection ChAdOx1-HBV, MVA-HBV, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Barinthus Biotherapeutics | 121 | 2022-09-21 | 2026-04-30 |
| A Study of Hepalatide Combined With TAF and PEG-IFN as Finite Treatment of Chronic Hepatitis B Patients Hepalatide, Placebo of Hepalatide, Tenofovir Alafenamide Tablets - Chronic Hepatitis B | Phase 2 | Completed | Shanghai HEP Pharmaceutical Co., Ltd. | 8 | 2022-08-23 | 2024-07-15 |
| Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection AB-729, Peg-IFNα-2a - Chronic Hepatitis b | Phase 2 | Completed | Arbutus Biopharma Corporation | 43 | 2021-10-29 | 2026-04-29 |
| A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With HBeAg-Negative Chronic Hepatitis B Treated With Nucleos(t)Ide Reverse Transcriptase Inhibitors NrtIs, HH-003, HH-003+NrtIs - Chronic Hepatitis B | Phase 2 | Completed | Huahui Health | 73 | 2021-10-09 | 2023-09-28 |
| Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) Tenofovir Alafenamide, VIR-2218, Nivolumab - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 103 | 2021-08-14 | 2025-07-24 |
| A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients ASC22, sodium chloride - Chronic Hepatitis b | Phase 2 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 207 | 2020-07-17 | 2024-12-02 |
| Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection VIR-2218, pegylated interferon-alfa 2a - Chronic Hepatitis B | Phase 2 | Completed | Vir Biotechnology, Inc. | 84 | 2020-07-03 | 2026-04-16 |
| Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study) ETV, TQ-A3334, TQ-B2450 - Chronic Hepatitis b | Phase 2 | Completed | Tongji Hospital | 24 | 2020-01-01 | 2026-10-06 |
| Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B Placebo Oral Tablet, Nitazoxanide - Chronic Hepatitis B | Phase 2 | Completed | Romark Laboratories L.C. | 51 | 2019-10-22 | 2023-11-07 |
| Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B VIR-2218, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Completed | Vir Biotechnology, Inc. | 82 | 2018-11-14 | 2021-12-13 |
| Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment Placebo, Selgantolimod, TAF - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 67 | 2018-08-28 | 2022-05-10 |
| A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV) ABI-H0731, SOC ETV, Placebo Oral Tablet - Chronic Hepatitis B | Phase 2 | Completed | Assembly Biosciences | 25 | 2018-06-19 | 2021-01-28 |
| A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection ABI-H0731, SOC NUC, Placebo Oral Tablet - Chronic Hepatitis B | Phase 2 | Completed | Assembly Biosciences | 73 | 2018-06-11 | 2021-02-17 |
| Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B Selgantolimod, Placebo, Hepatitis B virus (HBV) OAV Therapy - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 48 | 2018-04-06 | 2021-08-19 |
| The Safety, Antiviral Activity, and Pharmacokinetics of Morphothiadine Mesilate Capsules GLS4, RTV - Chronic Hepatitis B | Phase 2 | Completed | Sunshine Lake Pharma Co., Ltd. | 20 | 2017-07-26 | 2020-07-23 |
| Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) TAF - Chronic Hepatitis B | Phase 2 | Completed | Gilead Sciences | 124 | 2017-06-29 | 2021-09-27 |
| Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B ABI-H0731, Placebo for ABI-H0731, Entecavir - Chronic Hepatitis B | Phase 1 / Phase 2 | Completed | Assembly Biosciences | 38 | 2017-06-15 | 2018-07-06 |
Showing 20 of 52. Sign in to see all of them.
Hepatitis B, Chronic (52) · Hepatitis B (11) · Hepatitis (5) · Fibrosis (1) · Glomerulonephritis (1) · Hepatitis D (1) · Hepatitis D, Chronic (1) · Liver Diseases (1) · Polyarteritis Nodosa (1)
Blood-Borne Infections (52) · Chronic Disease (52) · Communicable Diseases (52) · DNA Virus Infections (52) · Digestive System Diseases (52) · Disease Attributes (52) · Hepadnaviridae Infections (52) · Hepatitis, Chronic (52) · Hepatitis, Viral, Human (52) · Infections (52) · Pathologic Processes (52) · Pathological Conditions, Signs and Symptoms (52) · Virus Diseases (52) · Liver Diseases (51) · Hepatitis (47)
entecavir (11) · Tenofovir (8) · peginterferon alfa-2a (8) · tenofovir alafenamide (6) · Emtricitabine (3) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (3) · selgantolimod (3) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (2) · Interferon alpha-2 (2) · Lamivudine (2) · Nivolumab (2) · vesatolimod (2) · Colony-Stimulating Factors (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hepatitis B Vaccines (1)
Gilead Sciences (13) · Bristol-Myers Squibb (4) · Assembly Biosciences (3) · Chongqing Jiachen Biotechnology Ltd. (3) · LG Life Sciences (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · Vir Biotechnology, Inc. (2) · Xiamen Amoytop Biotech Co., Ltd. (2) · Abivax S.A. (1) · Arbutus Biopharma Corporation (1) · Ascletis Pharmaceuticals Co., Ltd. (1) · Barinthus Biotherapeutics (1) · Beijing Bio-Fortune Ltd. (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Chinese University of Hong Kong (1)
China (19) · United States (15) · New Zealand (13) · South Korea (12) · Hong Kong (10) · Canada (9) · Taiwan (8) · Australia (7) · United Kingdom (6) · Italy (5) · France (4) · Germany (4) · Singapore (4) · Thailand (4) · Japan (2)
Lai Wei, Ph.D. (2) · Ching-Lung Lai, Dr (1) · George Lau, MD (1) · Henry LY Chan, MD (1) · John Flaherty, PharmD (1) · Junqi Niu, MD (1) · Junqi Niu, doctor (1) · LanJuan Li, Ph.D. (1) · Lewis Teperman, MD (1) · Marc G Ghany, M.D. (1) · Ming-Yang Lai, Professor (1)
PMID 16871563, PMID 18191272, PMID 18199519, PMID 19052126, PMID 19998272, PMID 20091678, PMID 20600025, PMID 21254162, PMID 24394187, PMID 24555998, PMID 29104121, PMID 29378197, PMID 29851204, PMID 30930022, PMID 32147484, PMID 33437904, PMID 34396571, PMID 34558823, PMID 34741731, PMID 35460726, PMID 35697332, PMID 37290591, PMID 38133554, PMID 38901444, PMID 39389081, PMID 39425534, PMID 39815989, PMID 40744841, PMID 40808966
2014 (2), 2015 (1), 2016 (1)